Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis

Stefanie Schlager,Carina Salomon,Sabine Olt,Christoph Albrecht,Anja Ebert,Oliver Bergner,Johannes Wachter,Francesca Trapani,Daniel Gerlach,Tilman Voss,Anna Traunbauer,Julian Jude,Matthias Hinterndorfer,Martina Minnich,Norbert Schweifer,Sophia M. Blake,Vittoria Zinzalla,Barbara Drobits,Darryl B. McConnell,Norbert Kraut,Mark Pearson,Johannes Zuber,Manfred Koegl

DOI: https://doi.org/10.18632/oncotarget.27506

2020-03-03

Oncotarget

Abstract:Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphomas worldwide and is characterized by a high diversity of genetic and molecular alterations. Chromosomal translocations and mutations leading to deregulated expression of the transcriptional repressor BCL6 occur in a significant fraction of DLBCL patients. An oncogenic role of BCL6 in the initiation of DLBCL has been shown as the constitutive expression of BCL6 in mice recapitulates the pathogenesis of human DLBCL. However, the role of BCL6 in tumor maintenance remains poorly investigated due to the absence of suitable genetic models and limitations of pharmacological inhibitors. Here, we have utilized tetracycline-inducible CRISPR/Cas9 mutagenesis to study the consequences of BCL6 deletion in established DLBCL models in culture and <i>in vivo</i>. We show that BCL6 knock-out in SU-DHL-4 cells <i>in vitro</i> results in an anti-proliferative response 4-7 days after Cas9 induction that was characterized by cell cycle (G1) arrest. Conditional BCL6 deletion in established DLBCL tumors <i>in vivo</i> induced a significant tumor growth inhibition with initial tumor stasis followed by slow tumor growth kinetics. Our findings support a role of BCL6 in the maintenance of lymphoma growth and showcase the utility of inducible CRISPR/Cas9 systems for probing oncogene addiction.